Green Cross making all-out efforts for management normalization of Innocell

Green Cross Corp., the largest shareholder of Innocell, a cell therapeutics company, said in its regulatory filing Wednesday that it has decided to voluntarily restrict the selling of its equities over the next three years until August 28, 2015 as part of normalizing the management of Innocell.

Green Cross recently purchased 23.43 percent in shares of Innocell to take over the managerial rig...